Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry
NBER Working Paper No. 17188
---- Acknowledgements -----
We thank Tamer Abdelgawad, Serguey Braguinsky, Iain Cockburn, Marty Gaynor, David Greenstreet, Bart Hamilton, Lowell Taylor, Jerry Thursby, Kenneth Train, and Ellerie Weber, and as well as seminar participants at Emory, Cornell, Carnegie Mellon, Pittsburgh, IIM Bangalore, IIM Ahmedabad, Charles River Associates and Precision Health Economics for valuable comments and discussions. We thank Susan Jack, Margaret Warner and Robert Anderson for guidance in using the National Health Interview Survey, and we thank Antara Dutta for sharing her code with us as well as for extensive discussions on her related research. Programming assistance by Nachiket Sahoo, Anubrata Banerjee and Trupti Natu is appreciated. We are grateful for the time Dr. Terry Simon and Dr. Ronald Severtis spent explaining to us the treatment of hypertension. We also thank Alexandra Kondo and IMS Health Incorporated for their generous support and access to their data. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IMS Health Incorporated, any of its affiliated or subsidiary entities, or the National Bureau of Economic Research. The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IMS Health Incorporated or affiliate information service(s): IMS Midas™, IMS Lifecycle™, IMS National Disease and Therapeutic Index™, IMS National Prescription Audit™, June 1997 to December 2008, IMS Health Incorporated or its affiliates. Higgins acknowledges funding from The Imlay Professorship and Pfizer, Inc. Chatterjee and Branstetter acknowledge funding from NSF SCISIP Grant #0830233.